Following the previous discussion on how data feasibility differs between fit-for-purpose RWE studies and fit-for-training AI systems, and the technical characteristics that support each assessment, the next question is a practical one: how should organizations actually build a data strategy that can support both?
Because once you determine that the same dataset must serve two fundamentally different models (regulatory-grade evidence generation on one side and machine learning deployment on the other) the challenge becomes architectural and organizational.
A dual-purpose strategy starts from intent, not infrastructure
In most healthcare organizations, data strategy historically evolved from retrospective analytics needs. RWE strengthened this further by formalizing how datasets are evaluated against study protocols and endpoints. AI, however, introduces a different situation: the data is not only used to explain what happened, but to predict what will happen under future conditions.
This distinction changes the starting point of the strategy. Rather than beginning with available data assets, mature organizations define two parallel intended uses: one anchored in regulatory and epidemiological inference, and another anchored in predictive system development. These two intentions then shape everything downstream, from data modeling to governance.
The architecture must separate fidelity, standardization, and learning
Once intent is clarified, the most important structural decision is to avoid collapsing all data processing into a single pipeline. In practice, successful organizations separate the data ecosystem into three conceptual layers.
The first layer preserves raw data in its original form, whether it originates from electronic health records (EHRs), claims systems, registries, imaging platforms, or physiological monitoring devices. This layer exists primarily to ensure traceability and auditability, which is essential for regulatory-grade RWE.
On top of this sits a standardized layer, most commonly implemented through a common data model (CDM) such as OMOP. This layer is where RWE becomes operationalized: cohorts are defined, endpoints are harmonized, and studies become reproducible across sites and time. It is the pillar of regulatory evidence generation.
The third layer is where AI introduces a fundamentally new requirement. Here, data is not only standardized but transformed into time-aware, machine-learnable representations. Features are explicitly aligned to prediction time, temporal windows are defined, and derived signals, such as trends, variability, or embeddings, are constructed to support learning algorithms. This layer is what makes the same underlying data usable for model training and deployment, rather than only for retrospective analysis.
Feasibility becomes a dual-axis evaluation problem
Once this layered architecture is established, data feasibility can no longer be treated as a single checklist exercise. In practice, it is necessary to move toward a dual-axis assessment.
From a RWE perspective, feasibility continues to focus on classical concerns such as cohort identification, endpoint validity, confounding structure, and follow-up completeness. This aligns with established regulatory thinking and structured frameworks used in RWE planning.
From an AI perspective, however, feasibility introduces additional constraints that are not captured in traditional RWE evaluation. The key question is no longer only whether a variable exists, but whether it is available at the correct time relative to prediction, whether labels are learnable from the available signal, whether the data distribution supports generalization, and whether the underlying modalities are sufficient for the intended model type.
In other words, RWE asks whether the data supports valid inference, while AI asks whether the data supports generalizable prediction under deployment conditions.
Time becomes the structural pillar of AI readiness
One of the most important strategic changes in dual-purpose data systems is the explicit treatment of time as a modeling construct rather than a passive attribute.
RWE studies typically define time in terms of index dates, exposure windows, and follow-up periods. AI systems, in contrast, require a stricter formulation: a prediction time point, a defined historical feature window, and a future outcome window.
If this temporal structure is not embedded at the data architecture level, AI feasibility becomes fragile. Many datasets that are fully suitable for RWE fail for AI not because of missing variables, but because those variables are not temporally aligned with prediction constraints, creating hidden leakage risks.
Labels become shared assets rather than study-specific definitions
A similar transformation occurs in how outcomes and phenotypes are treated. In traditional RWE workflows, endpoints are often defined per study, even when based on common coding systems or clinical definitions.
In a dual-purpose strategy, this is no longer sufficient. Labels must be treated as reusable, versioned assets that can serve both statistical inference and machine learning. This requires standardization of phenotype definitions, governance of endpoint logic, and, where necessary, clinical adjudication processes that ensure consistency across sites and time.
Without this layer of standardization, RWE and AI pipelines gradually diverge, even when built on the same underlying data sources.
Validation must be designed into the data system itself
Another critical change is that validation becomes embedded into the data strategy.
For RWE, this involves ensuring external validity, sensitivity analyses, and robustness across populations and coding systems.
For AI, it requires explicit design for temporal validation, site-based generalization, and drift resistance.
In mature implementations, validation datasets and splitting strategies are defined at the data architecture level, not reconstructed ad hoc during model development. This ensures that both RWE studies and AI models are evaluated under consistent and reproducible conditions.
Governance becomes the integration mechanism
As complexity increases, governance moves from a compliance function to an enabling layer that connects RWE and AI. It ensures that data lineage is preserved across transformations, that cohort and feature definitions are versioned, that access is controlled consistently, and that auditability is maintained for both regulatory submissions and AI system monitoring.
In practice, governance becomes the mechanism that allows both disciplines to operate on a shared foundation without losing traceability or control.
Strategy depends on cross-functional alignment, not technical consolidation
Perhaps the most important realization in building a dual-purpose strategy is that success does not come from merging RWE and AI teams into a single structure. Instead, it comes from clearly defined but tightly connected domains: evidence generation, machine learning, and data platform engineering.
Each of these functions has distinct expertise, but they must operate on shared datasets and interoperable definitions. The failure mode in most organizations is semantic misalignment between these groups.
To bridge this, many mature organizations introduce hybrid roles that translate between epidemiological definitions and machine learning constructs, ensuring that neither RWE validity nor AI usability is lost in translation.
Closing perspective: from data assets to engineered systems
The central transformation underlying all of this is that healthcare data can no longer be treated as a passive asset repository. When data must simultaneously support regulatory inference and machine learning deployment, it becomes an engineered system with multiple operational states.
The organizations that will succeed are those that move beyond thinking in terms of “datasets for RWE” or “datasets for AI” and instead design integrated data ecosystems capable of supporting both scientific validity and predictive performance without compromising either.
Summary: Dual requirements for RWE and AI data strategy
| Dimension | RWE (Regulatory-grade evidence) | AI (Machine learning / deployment) | Strategic implication |
| Primary objective | Explain causal or associative relationships in a defined population | Predict outcomes and generalize to unseen data | Same data source, different validity criteria |
| Analytical logic | Study-driven (protocol, estimand, cohort definition) | Model-driven (prediction task, training objective) | Requires dual framing of every dataset |
| Data structure focus | Completeness of clinical variables for a predefined question | Temporal structure, feature engineering, prediction alignment | AI requires additional restructuring of RWE datasets |
| Time handling | Index dates, exposure windows, follow-up periods | Strict separation of feature window, prediction time, and outcome window | Time modeling is more explicit and central in AI |
| Labels / endpoints | Clinically and regulatorily validated outcomes | Learnable targets with sufficient signal and consistency | Shared ontology needed for both use cases |
| Data quality definition | Fit-for-purpose for a specific study (e.g., SPIFD, REQueST-style registry assessment) | Fit-for-training and generalization (GMLP, EU AI Act Article 10 principles) | One dataset can pass one and fail the other |
| Validation approach | External validity, sensitivity analyses, confounding control | Internal + external validation, temporal and site-based generalization | Validation must be designed at data architecture level |
| Key risk | Residual confounding, incomplete follow-up, misclassification | Data leakage, distribution shift, poor generalization | Different failure modes require different safeguards |
| Required data granularity | Structured clinical data often sufficient | May require high-frequency, multimodal, or time-resolved data (e.g., waveforms, imaging, text embeddings) | AI often needs richer or differently structured data |
| Core enabling layer | Common Data Model (e.g., OMOP) for reproducibility | Feature store + time-aware modeling layer | AI layer sits on top of RWE-ready infrastructure |
| Organizational dependency | Epidemiology, biostatistics, regulatory science | Machine learning engineering, data engineering, MLOps | Requires cross-functional translation layer |
